Regencell Bioscience
5 hedge funds and large institutions have $296K invested in Regencell Bioscience in 2022 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, reducing their positions, and 2 closing their positions.
0% more funds holding
Funds holding: 5 → 5 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
3.44% less ownership
Funds ownership: 5.93% → 2.49% (-3.4%)
32% less capital invested
Capital invested by funds: $434K → $296K (-$138K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$195K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$13.7K |
| 3 |
BlackRock
New York
|
+$6.82K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$4.18K |
| 5 |
Morgan Stanley
New York
|
+$4.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$371K |
| 2 |
Citigroup
New York
|
-$48K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Geode Capital Management
Boston,
Massachusetts
| $238K | +$195K | +259,008 | New |
|
|
2
UBS Group
Zurich,
Switzerland
| $25K | +$13.7K | +18,202 | +196% |
|
|
TRCT
3
Tower Research Capital (TRC)
New York
| $20K | +$4.18K | +5,548 | +34% |
|
|
4
BlackRock
New York
| $8K | +$6.82K | +9,044 | New |
|
|
5
Morgan Stanley
New York
| $5K | +$4.1K | +5,434 | +2,383% |
|
|
6
Qube Research & Technologies (QRT)
London,
United Kingdom
| – | -$371K | -658,502 | Closed |
|
|
7
Citigroup
New York
| – | -$48K | -85,120 | Closed |
|
RGC Hedge Fund Activity: Q2 2022 in Review
5 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Regencell Bioscience (RGC) for Q2 2022, worth a combined $296K — down 32% from $434K a quarter earlier.
Fund positioning in RGC was balanced in Q2 2022: 2 funds opened new positions, 2 closed out, 3 added to existing stakes and 0 trimmed.
The largest buyer was Geode Capital Management, opening a new position worth an estimated $195K. The largest seller was Qube Research & Technologies (QRT), exiting entirely with an estimated $371K sold.
- 5 institutional investors held Regencell Bioscience (RGC) as of Q2 2022, unchanged from Q1 2022.
- Funds reported $296K of Regencell Bioscience stock for Q2 2022, down 32% quarter-over-quarter.
- 2 funds opened new Regencell Bioscience positions in Q2 2022 and 2 closed out, a net change of 0 holders.
- The largest Regencell Bioscience buyer in Q2 2022 was Geode Capital Management, an estimated $195K added.
- The largest Regencell Bioscience seller in Q2 2022 was Qube Research & Technologies (QRT), an estimated $371K sold.
Based on aggregated 13F filings for Q2 2022.